Olon Group is pleased to announce that the site located in Settimo Torinese has been successfully inspected by the National Regulatory Body, Agenzia Italiana del Farmaco (AIFA). Previous AIFA inspection of Settimo Torinese site occurred in 2018.

Olon is also  pleased to announce that along with site inspection, AIFA officially approved the new line dedicated to the synthesis of Biological APIs with specifical reference to peptides with recombinant DNA technology. The line relies on advanced biotechnology.

 Settimo Torinese is a historical asset of the global manufacturing network of the Group and moreover represents a centre of excellence for biotechnological manufacturing. The site has recently been expanded, according to the Company strategy that is fostering the development of its biotechnological platform, both in terms of expertise and production capacity.